Skip to main content
Industry News
COVID-19 vaccine trial participant describes the process

Journalist Richard Fisher is among a 10,000-person cohort participating in a clinical trial of a SARS-CoV-2 vaccine candidate developed at the University of Oxford and based on a weakened chimpanzee adenovirus. The process has not been quick, easy or worry-free, and there's no guarantee that at the end of the trial, the vaccine will have been proven effective, which is something the public and many politicians don't understand about vaccine development, Fisher writes.

Full Story: